Baicalin
Based on 63 publication(s) in Google Scholar
Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (CPT1) activator. Baicalin reduces the expression of NF-κB.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.92%
- CAS No.: 21967-41-9
- Formule: C21H18O11
- Masse moléculaire:446.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N0196
BaicaleinXanthine Oxidase Inhibitor -
HY-18085
QuercetinFlavonoid Antioxidant -
HY-N0400
WogoninCDK Inhibitor -
HY-14393
EmodinNatural Anthraquinone -
HY-N0145
Puerarin5-HT Receptor Antagonist -
HY-18258
Berberine chlorideAntibiotic -
HY-N0751
ScutellarinSTAT Inhibitor -
HY-14590
KaempferolEstrogen Receptor α Inhibitor -
HY-N0293
PaeoniflorinHSP Activator -
HY-N0162
LuteolinNrf2 Inhibitor -
HY-N0184
Glycyrrhizic acidHMGB1 Antagonist -
HY-N0191
AndrographolideNF-κB Inhibitor
Publications Citing Use of MedChemExpress (MCE) Baicalin
More- Nat Commun. 2026 May 11;17(1):4190. [Abstract]
- Biosens Bioelectron. 2024 Nov 1:263:116630. [Abstract]
- Phytomedicine. 2026 Jan:150:157703. [Abstract]
- Phytomedicine. 2025 Sep 4:148:157233. [Abstract]
- Phytomedicine. 2025 Jul:142:156713. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Phytomedicine. 2024 Mar:125:155337. [Abstract]
- Phytomedicine. 2024 Jan:122:155162. [Abstract]
- Food Chem. 2025 Dec 30:497:146992. [Abstract]
- Food Chem. 2025 Oct 15:489:144992. [Abstract]
- Int J Surg. 2026 Feb 19. [Abstract]
- Int J Biol Macromol. 2025 Apr:302:140526. [Abstract]
- Antioxidants (Basel). 2024 Jan 17;13(1):115. [Abstract]
- Chin Med. 2022 Feb 18;17(1):23. [Abstract]
- J Ethnopharmacol. 2025 Jun 12:349:119964. [Abstract]
- Antioxid Redox Signal. 2025 Jan;42(1-3):53-76. [Abstract]
- J Ethnopharmacol. 2022 Mar 1:285:114786. [Abstract]
- Ecotoxicol Environ Saf. 2024 Aug:281:116661. [Abstract]
- Biochem Pharmacol. 2025 Sep 21;242(Pt 3):117360. [Abstract]
- Mol Metab. 2024 Jun:84:101953. [Abstract]
- Anal Chim Acta. 2025 Nov 22:1376:344623. [Abstract]
- Pharm Biol. 2020 Dec;58(1):655-663. [Abstract]
- Eur J Pharmacol. 2023 Jan 5:938:175425. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 2):115883. [Abstract]
- Int Immunopharmacol. 2025 Nov 30;168(Pt 2):115941. [Abstract]
- Int J Mol Sci. 2022 Dec 2;23(23):15155. [Abstract]
- Exp Gerontol. 2025 Jun 1:204:112743. [Abstract]
- Bioorg Chem. 2022 Feb:119:105538. [Abstract]
- Mol Med Rep. 2025 May;31(5):126. [Abstract]
- J Mol Struct. 2026 Sep 26;1350:144175.
- Sci Rep. 2025 May 12;15(1):16424. [Abstract]
- J Cell Mol Med. 2025 Nov;29(21):e70944. [Abstract]
- J Inflamm Res. 2025 May 30:18:6963-6981. [Abstract]
- J Inflamm Res. 2025 Feb 4:18:1543-1556. [Abstract]
- Poult Sci. 2025 Sep 11;104(11):105818. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2026 Jul 13.
- BMC Oral Health. 2025 Apr 10;25(1):513. [Abstract]
- Diabetes Metab Syndr Obes. 2023 Apr 26:16:1193-1205. [Abstract]
- J Pharm Biomed Anal. 2026 Mar 15:270:117281. [Abstract]
- Surgery. 2026 Mar 16:194:110148. [Abstract]
- Exp Eye Res. 2025 Sep:258:110487. [Abstract]
- Immunobiology. 2025 Jul 16;230(4):153103. [Abstract]
- Immunopharmacol Immunotoxicol. 2023 Dec;45(4):433-442. [Abstract]
- Oral Dis. 2019 Nov;25(8):1945-1953. [Abstract]
- Fitoterapia. 2026 Mar:189:107079. [Abstract]
- Toxicol Res (Camb). 2024 Sep 3;13(5):tfae134. [Abstract]
- Biomed Res Int. 2022 Nov 18:2022:3139123. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- J Cardiovasc Transl Res. 2026 Mar 27;19(1):45. [Abstract]
- Burns. 2025 Dec;51(9):107671. [Abstract]
- Biochem Biophys Res Commun. 2026 Jan 1:794:153036. [Abstract]
- Planta Med. 2025 Aug 8. [Abstract]
- J Recept Signal Transduct Res. 2022 Jun;42(3):230-240. [Abstract]
- Pharmacogn Mag. 2024 Apr 15.
- J Evol Biochem Physiol. 2026 Apr 19;62(2):295-308.
- SSRN. 2026 Mar 19.
- University of Arkansas. 2025.
- Biomed Pharmacother. 2025 Sep 17:192:118569. [Abstract]
- SSRN. 2025 Jul 8.
- Preprints. 2024 Jan 31.
- Research Square Preprint. 2023 May 10.
- Environ Sci Pollut Res Int. 2023 Apr;30(18):53997-54021. [Abstract]
- Research Square Preprint. 2022 Jul.
Customer Validation & Images
-
IF
-
Cell Proliferation/Viability Assay
-
WB
-
WB
-
IF
Activité biologique
Description
IC50 & Target
[1]|
NF-κB |
CPT-1 |
Autophagy |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-3 | CC50 |
>100 μM
Compound: 2
|
Cytotoxicity against human Calu-3 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay
Cytotoxicity against human Calu-3 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay
|
[PMID: 36965227] |
| Calu-3 | CC50 |
>100 μM
Compound: Baicalin
|
Cytotoxicity against human Calu-3 cells incubated for 4 days by MTS assay
Cytotoxicity against human Calu-3 cells incubated for 4 days by MTS assay
|
[PMID: 37437351] |
| CHO | IC50 |
>200 μM
Compound: 2
|
Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells
Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells
|
[PMID: 12713409] |
| H9 | EC50 |
112 μM
Compound: 8
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8158164] |
| H9 | IC50 |
72 μM
Compound: 8
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8158164] |
| HEK-293T | CC50 |
<=300 μM
Compound: Baicalin
|
Cytotoxicity against HEK293T cells expressing human ACE2 assessed as reduction in cell viability incubated for 4 hrs by MTT assay
Cytotoxicity against HEK293T cells expressing human ACE2 assessed as reduction in cell viability incubated for 4 hrs by MTT assay
|
[PMID: 37437351] |
| HUVEC | IC50 |
>1000 μM
Compound: 2
|
Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA
|
[PMID: 9214730] |
| MGC-803 | IC50 |
8.78 μM
Compound: 50
|
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33619958] |
| MGC-803 | IC50 |
8.78 μM
Compound: 5
|
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 33945992] |
| RAW264.7 | IC50 |
156.8 μM
Compound: 1
|
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in NO production
|
[PMID: 37778427] |
| RAW264.7 | IC50 |
35.2 μg/mL
Compound: 1
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction in NO production compound photoirradiated using 50 kGy gamma-ray
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction in NO production compound photoirradiated using 50 kGy gamma-ray
|
[PMID: 37778427] |
| Vero | IC50 |
13.5 μg/mL
Compound: 74
|
Antiviral activity against DENV2 infected in African green monkey Vero cells by focus formation unit reduction assay
Antiviral activity against DENV2 infected in African green monkey Vero cells by focus formation unit reduction assay
|
[PMID: 31128447] |
| Vero | CC50 |
>100 μM
Compound: Baicalin
|
Cytotoxicity against African green monkey Vero cells incubated for 4 days by MTS assay
Cytotoxicity against African green monkey Vero cells incubated for 4 days by MTS assay
|
[PMID: 37437351] |
| Vero | CC50 |
>200 μM
Compound: Baicalin
|
Cytotoxicity against African green monkey Vero cells
Cytotoxicity against African green monkey Vero cells
|
[PMID: 37437351] |
| Vero C1008 | CC50 |
>200 μM
Compound: Baicalin
|
Cytotoxicity against African green monkey Vero E6 cells incubated for 3 hrs by CCK-8 assay
Cytotoxicity against African green monkey Vero E6 cells incubated for 3 hrs by CCK-8 assay
|
[PMID: 33186044] |
| Vero C1008 | CC50 |
>100 μM
Compound: 2
|
Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay
Cytotoxicity against african green monkey Vero E6 cells assessed as inhibition of cell growth incubated for 4 days by MTS assay
|
[PMID: 36965227] |
| Vero C1008 | CC50 |
>1000 μM
Compound: Baicalin
|
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 37437351] |
| Vero C1008 | CC50 |
>200 μM
Compound: 85
|
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell growth incubated for 24 hrs by WST-8 assay
|
[PMID: 37597436] |
In Vitro
Baicalin protects against ischemia-reperfusion injury (IRI) by altering the production of various mediators, including reactive oxygen species (ROS), Toll-like receptor (TLR)2 and TLR4, NF-κB, Bax, and Bcl-2. Baicalin treatment inhibits the increased expression of the proinflammatory cytokines TLR2/4, MyD88, p-NF-κB, and p- IκB, as well as increase the expression of IκB protein, an NF-κB inhibitor[1].
Cell viability is determined by MTT assay. Compared with control cells, cell viability is significantly decreased in SH-SY5Y cells treated with thrombin. Pre-treatment with Baicalin (5, 10, 20 μM) increases cell viability in a dose-dependent manner compared with cells treated thrombin alone[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 21967-41-9
-
Appearance Solid
-
Masse moléculaire 446.36
-
Formule C21H18O11
-
Color Light yellow to yellow
-
SMILES
O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=C(O)C(O)=C3C(C=C(C4=CC=CC=C4)OC3=C2)=O
-
Synonyms
Baicalein 7-O-β-D-glucuronide
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (63)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. [Abstract]2026 May 11;17(1):4190. PMID: 42115216 -
Biosens Bioelectron
Engineering a NanoBiT biosensor for detecting angiotensin-converting enzyme-2 (hACE2) interaction with SARS-CoV-2 spike protein and screening the inhibitors to block hACE2 and spike interaction. [Abstract]2024 Nov 1:263:116630. PMID: 39102773 -
Phytomedicine
Baicalin attenuates pulmonary hypertension by targeting AMPK/CPT1A-mediated fatty acid metabolism. [Abstract]2026 Jan:150:157703. PMID: 41447844 -
Phytomedicine
Huang-Lian-Jie-Du decoction enhances Capecitabine-Oxaliplatin efficacy via Akkermansia muciniphila and CD8+ T cells in colorectal cancer. [Abstract]2025 Sep 4:148:157233. PMID: 40972261 -
Phytomedicine
Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]2025 Jul:142:156713. PMID: 40349422 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Phytomedicine
Baicalin and N-acetylcysteine regulate choline metabolism via TFAM to attenuate cadmium-induced liver fibrosis. [Abstract]2024 Mar:125:155337. PMID: 38241915 -
Phytomedicine
Baicalin ameliorates renal fibrosis by upregulating CPT1α-mediated fatty acid oxidation in diabetic kidney disease. [Abstract]2024 Jan:122:155162. PMID: 37922789 -
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530 -
Int J Surg
Intelligent identification and targeted intervention of GRP75-caused drug resistant hepatocellular carcinoma, a study based on radiomics, machine learning, and molecular pharmacology. [Abstract]2026 Feb 19. PMID: 41711200 -
Int J Biol Macromol
High-throughput virtual screening and empirical validation of probable inhibitors of Plasmodium falciparum and vivax glutathione transferase using bromosulfophthalein as the benchmark ligand. [Abstract]2025 Apr:302:140526. PMID: 39892549 -
Antioxidants (Basel)
Role of Mitochondrial Reactive Oxygen Species-Mediated Chaperone-Mediated Autophagy and Lipophagy in Baicalin and N-Acetylcysteine Mitigation of Cadmium-Induced Lipid Accumulation in Liver. [Abstract]2024 Jan 17;13(1):115. PMID: 38247538
Baicalin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Jan 17;13(1):115. [Abstract]
20 mg/kg baicalin was administered orally by gavage to mice for 90 days. DHE staining was performed to observe the content of superoxide anions in tissues.
Baicalin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Jan 17;13(1):115. [Abstract]
Cells were treated with 5 µM Cd, 10 µM baicalin, and 20 µM NAC, alone or in combination, for 12 h.
Baicalin purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Jan 17;13(1):115. [Abstract]
Cells were treated with 5 µM Cd, 10 µM baicalin, and 20 µM NAC alone or in combination for 12 h.
-
Chin Med
Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence. [Abstract]2022 Feb 18;17(1):23. PMID: 35180857 -
J Ethnopharmacol
Integrating bioinformatic analysis, network pharmacology, molecular docking and experimental validation to explore the mechanism of Tian Long Cha against influenza virus. [Abstract]2025 Jun 12:349:119964. PMID: 40368255 -
Antioxid Redox Signal
Baicalin Attenuates Diabetic Cardiomyopathy In Vivo and In Vitro by Inhibiting Autophagy and Cell Death through SENP1/SIRT3 Signaling Pathway Activation. [Abstract]2025 Jan;42(1-3):53-76. PMID: 38687336 -
J Ethnopharmacol
Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [Abstract]2022 Mar 1:285:114786. PMID: 34763043 -
Ecotoxicol Environ Saf
Baicalin protects against hepatocyte injury caused by aflatoxin B1 via the TP53-related ferroptosis Pathway. [Abstract]2024 Aug:281:116661. PMID: 38954907 -
Biochem Pharmacol
Chemoproteomics-based profiling reveals the targeting molecular mechanism of reversal of cisplatin resistance by baicalin in head and neck squamous cell carcinoma. [Abstract]2025 Sep 21;242(Pt 3):117360. PMID: 40987408 -
Mol Metab
Long-chain acyl-CoA synthetase-4 regulates endometrial decidualization through a fatty acid β-oxidation pathway rather than lipid droplet accumulation. [Abstract]2024 Jun:84:101953. PMID: 38710444 -
Anal Chim Acta
An in vivo NanoBiT-based pseudoviral biosensor for real-time monitoring of SARS-CoV-2 spike/hACE2 interactions and therapeutic screening. [Abstract]2025 Nov 22:1376:344623. PMID: 41073017 -
Pharm Biol
Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway. [Abstract]2020 Dec;58(1):655-663. PMID: 32649845 -
Eur J Pharmacol
Baicalin prevents fibrosis of human trabecular meshwork cells via inhibiting the MyD88/NF-κB pathway. [Abstract]2023 Jan 5:938:175425. PMID: 36442621 -
Int Immunopharmacol
Baicalin inhibits the Akt/mTOR/ULK1 signaling pathway to activate autophagy and ameliorate pulmonary fibrosis. [Abstract]2026 Jan 1;168(Pt 2):115883. PMID: 41308360 -
Int Immunopharmacol
Baicalin ameliorates Aspergillus fumigatus keratitis by its antifungal activity and suppression of pyroptosis. [Abstract]2025 Nov 30;168(Pt 2):115941. PMID: 41325669 -
Int J Mol Sci
TRPV4 Promotes Metastasis in Melanoma by Regulating Cell Motility through Cytoskeletal Rearrangement. [Abstract]2022 Dec 2;23(23):15155. PMID: 36499486 -
Exp Gerontol
Baicalin alleviates intervertebral disc degeneration by inhibiting the p38 MAPK signaling pathway. [Abstract]2025 Jun 1:204:112743. PMID: 40174870 -
Bioorg Chem
Baicalin ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice through modulating skin barrier function, gut microbiota and JAK/STAT pathway. [Abstract]2022 Feb:119:105538. PMID: 34929516 -
Mol Med Rep
Exosomes derived from baicalin‑pretreated mesenchymal stem cells mitigate atherosclerosis by regulating the SIRT1/NF‑κB signaling pathway. [Abstract]2025 May;31(5):126. PMID: 40084693 -
-
Sci Rep
Baicalin prevents experimental autoimmune uveitis by promoting macrophage polarization balance through inhibiting the HIF-1α signaling pathway. [Abstract]2025 May 12;15(1):16424. PMID: 40355594 -
J Cell Mol Med
Jinbei Decoction Attenuates LPS-Induced Acute Lung Injury via Suppression of TRAF6-Dependent Inflammatory Response in Macrophage. [Abstract]2025 Nov;29(21):e70944. PMID: 41230791 -
J Inflamm Res
Unveiling the Therapeutic Potential of Baicalin in Intervertebral Disc Degeneration: Integrative Bulk and Single-Cell Transcriptome Analysis with Experimental Validation of PANoptosis Inhibition. [Abstract]2025 May 30:18:6963-6981. PMID: 40463856 -
J Inflamm Res
Effects of Baicalin on Gout Based on Network Pharmacology, Molecular Docking, and in vitro Experiments. [Abstract]2025 Feb 4:18:1543-1556. PMID: 39925939 -
Poult Sci
Baicalin alleviates oxidative stress in DF-1 cell line via the Mfn2/MAMs/Ca (2+) pathway. [Abstract]2025 Sep 11;104(11):105818. PMID: 40974997 -
-
BMC Oral Health
Baicalin attenuates LPS-induced periodontal inflammation response by inhibiting autophagy. [Abstract]2025 Apr 10;25(1):513. PMID: 40211339 -
Diabetes Metab Syndr Obes
Baicalin Exerts a Protective Effect in Diabetic Nephropathy by Repressing Inflammation and Oxidative Stress Through the SphK1/S1P/NF-κB Signaling Pathway. [Abstract]2023 Apr 26:16:1193-1205. PMID: 37131503 -
J Pharm Biomed Anal
Identification of new small molecule inhibitors of PD-1/PD-L1 interaction by a comprehensive ligand fishing system. [Abstract]2026 Mar 15:270:117281. PMID: 41308584 -
Surgery
Baicalin attenuates burn wound progression by suppressing PANoptosis in the zone of stasis. [Abstract]2026 Mar 16:194:110148. PMID: 41844447 -
Exp Eye Res
Baicalin ameliorates inflammation response in diabetic dry eye models through the inhibition of the PERK/TXNIP/NLRP3 pathway. [Abstract]2025 Sep:258:110487. PMID: 40517884 -
Immunobiology
Exosomes derived from baicalin-pretreated bone marrow mesenchymal stem cells inactivate the TLR4/MyD88/NF-kB pathway to improve asthma. [Abstract]2025 Jul 16;230(4):153103. PMID: 40695068 -
Immunopharmacol Immunotoxicol
Baicalin suppresses interleukin-1β-induced apoptosis, inflammatory response, oxidative stress, and extracellular matrix degradation in human nucleus pulposus cells. [Abstract]2023 Dec;45(4):433-442. PMID: 36617937 -
Oral Dis
Anti-inflammatory effect of paeoniflorin combined with baicalin in oral inflammatory diseases. [Abstract]2019 Nov;25(8):1945-1953. PMID: 31393636
Baicalin purchased from MedChemExpress. Usage Cited in: Oral Dis. 2019 Nov;25(8):1945-1953. [Abstract]
PF and BAI combination suppresses activation of the NF-κB signaling pathway in LPS-treated HOKs. Western blotting assay is performed to investigate expression of NF-κB inflammatory signaling proteins.
Baicalin purchased from MedChemExpress. Usage Cited in: Oral Dis. 2019 Nov;25(8):1945-1953. [Abstract]
The nuclear translocation of NF-κB p65 was visualized using a laser confocal scanning microscope imaging system. Nuclei detected with DAPI (blue). Cells expressing NF-κB p65 in the cytoplasm (green). NF-κB p65 expresses mostly in the nucleus, and a small amount expressed in the cytoplasm (green). Localization of NF-κB p65 in the cytoplasm (green).
-
Fitoterapia
2026 Mar:189:107079. PMID: 41485687 -
Toxicol Res (Camb)
Effect of baicalin and baicalin-bovine serum albumin nanoparticle against bendiocarb exposure in rats. [Abstract]2024 Sep 3;13(5):tfae134. PMID: 39233847 -
Biomed Res Int
2022 Nov 18:2022:3139123. PMID: 36440360 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
J Cardiovasc Transl Res
Baicalin Attenuates Oxidative Stress and Apoptosis in Myocardial Ischemia/reperfusion Injury via Suppression of STING/NLRP3 Pathway. [Abstract]2026 Mar 27;19(1):45. PMID: 41894055 -
Burns
Baicalin promotes the survival of flaps by downregulating the JAK2-STAT3 signaling pathway. [Abstract]2025 Dec;51(9):107671. PMID: 40939303 -
Biochem Biophys Res Commun
Baicalin inhibits bladder cancer progression by suppressing PD-L1-mediated M2 macrophage polarization via ALDH2. [Abstract]2026 Jan 1:794:153036. PMID: 41330073 -
Planta Med
Baicalein Alleviates Neuropathic Pain by Inhibiting Microglial Activation and Inflammation Via the TLR4/NF-κB p65 Pathway. [Abstract]2025 Aug 8. PMID: 40719141 -
J Recept Signal Transduct Res
Baicalin regulates the development of pediatric asthma via upregulating microRNA-103 and mediating the TLR4/NF-κB pathway. [Abstract]2022 Jun;42(3):230-240. PMID: 33730981 -
-
-
-
-
Biomed Pharmacother
Baicalin attenuates acetaminophen-induced acute liver injury through inhibiting TLR2-dependent neutrophil extracellular trap formation. [Abstract]2025 Sep 17:192:118569. PMID: 40967078 -
-
-
-
Environ Sci Pollut Res Int
The protective effects of baicalin and chrysin against emamectin benzoate-induced toxicity in Wistar albino rats. [Abstract]2023 Apr;30(18):53997-54021. PMID: 36869176 -
Solvant et solubilité
In Vitro:
DMSO : ≥ 100 mg/mL (224.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.60 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (44.81 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lin M, et al. The protective effect of Baicalin against renal ischemia-reperfusion injury through inhibition of inflammation and apoptosis. BMC Complement Altern Med. 2014 Jan 13;14:19. [Content Brief]
[2]. Ju XN, et al. Baicalin protects against thrombin induced cell injury in SH-SY5Y cells. Int J Clin Exp Pathol. 2015 Nov 1;8(11):14021-7. [Content Brief]
[3]. Dai J, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci U S A. 2018;115(26):E5896-E5905. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2403 mL | 11.2017 mL | 22.4034 mL | 56.0086 mL |
| 5 mM | 0.4481 mL | 2.2403 mL | 4.4807 mL | 11.2017 mL | |
| 10 mM | 0.2240 mL | 1.1202 mL | 2.2403 mL | 5.6009 mL | |
| 15 mM | 0.1494 mL | 0.7468 mL | 1.4936 mL | 3.7339 mL | |
| 20 mM | 0.1120 mL | 0.5601 mL | 1.1202 mL | 2.8004 mL | |
| 25 mM | 0.0896 mL | 0.4481 mL | 0.8961 mL | 2.2403 mL | |
| 30 mM | 0.0747 mL | 0.3734 mL | 0.7468 mL | 1.8670 mL | |
| 40 mM | 0.0560 mL | 0.2800 mL | 0.5601 mL | 1.4002 mL | |
| 50 mM | 0.0448 mL | 0.2240 mL | 0.4481 mL | 1.1202 mL | |
| 60 mM | 0.0373 mL | 0.1867 mL | 0.3734 mL | 0.9335 mL | |
| 80 mM | 0.0280 mL | 0.1400 mL | 0.2800 mL | 0.7001 mL | |
| 100 mM | 0.0224 mL | 0.1120 mL | 0.2240 mL | 0.5601 mL |
Baicalin Related Classifications
HY-N0197 Related Classifications
Powered by Bioz